>>I can't think of one company which has recently gotten approval that isn't dramatically lower then the announcement day
ACOR is about 20% higher than it was on its approval date in January this year.
I don't disagree with you on the "manipulation" theories though.
Some months ago I said on this forum that I though the most likely outcome was MNTA approval and a Teva "no decision." Looks like that is where we are. My current guess is that Teva will have to resubmit, and so a competitor is a year or two off. Meantime MNTA should make a fair amount of money, although I believe the Teva overhang will continue to prevent MNTA receiving a decent PE multiple.
My view is nevertheless that MNTA stock will outperform over the next year though.
The difference here is that MNTA had no run-up to approval. It just came out of nowhere, due to the nature of ANDA's. Plus, I think some people were surprised that TEVA did not get approval as well.
Market Data 
Markets 
AI
